Assessment of cognitive safety in clinical drug development

Cognitive impairment is increasingly recognised as an important potential adverse effect of medication. However, many drug development programmes do not incorporate sensitive cognitive measurements. Here, we review the rationale for cognitive safety assessment, and explain several basic methodologic...

Descripción completa

Detalles Bibliográficos
Autores principales: Roiser, Jonathan P., Nathan, Pradeep J., Mander, Adrian P., Adusei, Gabriel, Zavitz, Kenton H., Blackwell, Andrew D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863933/
https://www.ncbi.nlm.nih.gov/pubmed/26610416
http://dx.doi.org/10.1016/j.drudis.2015.11.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863933/
https://www.ncbi.nlm.nih.gov/pubmed/26610416
http://dx.doi.org/10.1016/j.drudis.2015.11.003

Ejemplares similares